Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Innate Pharma (IPHA) Research & Development (2019 - 2025)

Historic Research & Development for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to -$23.2 million.

  • Innate Pharma's Research & Development rose 2581.72% to -$23.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$170.4 million, marking a year-over-year decrease of 3532.49%. This contributed to the annual value of $55.5 million for FY2024, which is 784.84% down from last year.
  • Per Innate Pharma's latest filing, its Research & Development stood at -$23.2 million for Q2 2025, which was up 2581.72% from -$55.5 million recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Research & Development registered a high of $705703.1 during Q2 2021, and its lowest value of -$60.3 million during Q4 2023.
  • In the last 5 years, Innate Pharma's Research & Development had a median value of -$31.3 million in 2024 and averaged -$31.6 million.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 10203.4% in 2021, then plummeted by 11425668.68% in 2023.
  • Over the past 5 years, Innate Pharma's Research & Development (Quarter) stood at -$53.8 million in 2021, then surged by 99.9% to -$52709.0 in 2022, then plummeted by 114256.69% to -$60.3 million in 2023, then grew by 7.85% to -$55.5 million in 2024, then surged by 58.18% to -$23.2 million in 2025.
  • Its Research & Development stands at -$23.2 million for Q2 2025, versus -$55.5 million for Q4 2024 and -$31.3 million for Q2 2024.